Your session is about to expire
← Back to Search
HSP90 Inhibitor
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
Phase 2
Waitlist Available
Led By Jeffrey W Clark, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
In this research study, the investigators are looking to see how effective STA-9090 is in treating esophagogastric cancer. The investigators will also evaluate the side effects of STA-9090, and examine the relationship between the presence of HSP-90 and how well study participants respond to STA-9090. STA-9090 works by blocking a protein in tumor cells called HSP90, which is thought to play a role in tumor growth. By interfering with this protein's function, STA-9090 may help kill tumor cells. This drug has been used in other research studies and information from those other research studies suggests that this agent may help to slow tumor growth in esophagogastric cancer.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2012 Phase 2 trial • 20 Patients • NCT0111183867%
Alkaline phosphatase
60%
AST, SGOT
60%
Diarrhea
60%
Fatigue (asthenia, lethargy, malaise)
47%
ALT, SGPT
47%
Glucose, high (hyperglycemia)
40%
Lymphopenia
40%
Albumin, low (hypoalbuminemia)
40%
Bilirubin (hyperbilirubinemia)
33%
Phosphate, low (hypophosphatemia)
33%
Hemoglobin
27%
Amylase
27%
Lipase
27%
Nausea
27%
Pain - Abdomen NOS
20%
Anorexia
20%
Neutrophils/granulocytes (ANC/AGC)
20%
Sodium, low (hyponatremia)
20%
Leukocytes (total WBC)
13%
Metabolic/Lab
13%
Vomiting
13%
Constitutional Symptoms
13%
Dyspnea (shortness of breath)
13%
Fever (in the absence of neutropenia)
13%
INR
7%
Ascites (non-malignant)
7%
Allergy reaction (including drug fever)
7%
CPK (creatine phosphokinase)
7%
Magnesium, low (hypomagnesemia)
7%
Obstruction, GI- Small bowel NOS
7%
PTT
7%
Potassium, low (hypokalemia)
7%
Rash/desquamation
7%
Sweating (diaphoresis)
7%
Tinnitus
7%
Neurology - Other (specify)
7%
Obstruction, GI- Colon
7%
Dental: dentures or prosthesis
7%
Distension/bloating, abdominal
7%
Dizziness
7%
Gastrointestinal, other
100%
80%
60%
40%
20%
0%
Study treatment Arm
Patients With Refractory Metastatic Colorectal Cancer
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: STA-9090Experimental Treatment1 Intervention
All subjects receive STA-9090
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ganetespib
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
3,026 Previous Clinical Trials
13,413,761 Total Patients Enrolled
Dana-Farber Cancer InstituteOTHER
1,113 Previous Clinical Trials
358,853 Total Patients Enrolled
Beth Israel Deaconess Medical CenterOTHER
861 Previous Clinical Trials
12,932,798 Total Patients Enrolled
Synta Pharmaceuticals Corp.Industry Sponsor
37 Previous Clinical Trials
3,137 Total Patients Enrolled
Jeffrey W Clark, MDPrincipal InvestigatorMassachusetts General Hospital
1 Previous Clinical Trials
35 Total Patients Enrolled